

11 May 2020

**ANTICIPATED ACQUISITION BY PHARM-A-CARE LABORATORIES
PTY LIMITED OF THE HALIBORANGE BUSINESS OF THE
PROCTER & GAMBLE COMPANY**

**Notice under section 96(2A) of the Enterprise Act 2002 (the Act)
published pursuant to section 107(1)(i) of the Act**

The Competition and Markets Authority (CMA) hereby gives notice pursuant to section 96(2A) of the Act that the merger notice provided by Pharm-a-Care Laboratories Pty Limited in relation to the anticipated acquisition by Pharm-a-Care Laboratories Pty Limited of the Haliborange business of the Procter & Gamble Company (the **Merger**) meets the requirements of section 96(2) of the Act.

The initial period defined in section 34ZA(3) of the Act in relation to the Merger will therefore commence on the first working day after the date of this notice, ie on 12 May 2020. The deadline for the CMA to announce its decision whether to refer the Merger for a Phase 2 investigation is therefore 7 July 2020.